Histone deacetylases, and uses related thereto
AssigneePresident and Fellows of Harvard College
InventorsStuart L. Schreiber, Jack Taunton, Christian A. Hassig, Timothy F. Jamison
Life of this patent
Estimating the term…
Abstract
The present invention concerns the discovery that proteins encoded by a family of genes, termed here HDx-related genes, which are involved in the control of chromatin structure and, thus in transcription and translation. The present invention makes available compositions and methods that can be utilized, for example to control cell proliferation and differentiation in vitro and in vivo.
Claims13
1-48. (canceled)
A method for modulating one or more of growth, differentiation, or survival of a mammalian cell responsive to HDx-mediated histone deacetylation, comprising treating the cell with an effective amount of an agent which modulates the deacetylase activity of an HDx polypeptide thereby altering, relative to the cell in the absence of the agent at least one of (i) rate of growth, (ii) differentiation, or (iii) survival.
50-82. (canceled)
A method for treating anomalous cell proliferation selected from the group consisting of psoriasis, bone diseases, fibroproliferative disorders, atherosclerosis and smooth muscle proliferative disorders comprising administering an effective amount of an agent which modulates the deacetylase activity of an HDx polypeptide.
A method for treating differentiative disorders selected from the group consisting of chronic neurodegenerative diseases of the nervous system, Alzheimer's disease, Parkinson's disease, Huntington's chorea, amylotrophic lateral sclerosis, spinocerebellar degeneration, differentiative disorders associated with connective tissue, vascular disorders which involve de-differentiation of endothelial tissue and smooth muscle cells, gastric ulcers characterized by degenerative changes in glandular cells, and renal conditions marked by failure to differentiate, and Wilm's tumors comprising administering an effective amount of an agent which modulates the deacetylase activity of an HDx polypeptide.
A method for treating antigen-specific tolerance selected from the group consisting of autoimmune diseases, tolerance in allogeneic or xenogeneic transplant recipients, or graft versus host (GVH) reactions comprising administering an effective amount of an agent which modulates the deacetylase activity of an HDx polypeptide.
Dependencies are inferred from the claim text.